Psychedelic Ethics in Palliative Care.
Am J Bioeth January 13, 2025 Keenan Davis, Roman Palitsky, Boadie W. Dunlop et al. 3 citations
Cohen and Marks (2025) argue for a middle path between two extreme views on psychedelic medicine: the exceptionalism that overstates its unique therapeutic potential and the skepticism that dismisses it as no different from other treatments. They contend that psychedelics do possess distinctive features—such as their capacity to induce profound altered states and facilitate enduring psychological change—but that these features do not warrant special regulatory or ethical exemptions. The authors advocate for integrating psychedelic therapies into existing medical frameworks while acknowledging their specific risks and benefits, aiming to balance innovation with responsible oversight.